ReCode Therapeutics nabs $80m Series A
ReCode Therapeutics, a provider of precision medicines for pulmonary diseases, has raised $80 million in Series A financing.
ReCode Therapeutics, a provider of precision medicines for pulmonary diseases, has raised $80 million in Series A financing.